A study to evaluate efficacy and safety of docetaxel combined with dexamethasone in patients with hormone refractory prostate cancer; JMTO PCa10-01
Not Applicable
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000004096
- Lead Sponsor
- The Japan-Multinational Trial Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 75
Inclusion Criteria
Not provided
Exclusion Criteria
1. No prior cyto-toxic chemotherapy and/or molecular targeting therapy, including mono-therapy of estramustine. 2. Infection. 3. Fever with suspicion of infectious disease. 4. Interstitial pneumonitis and pulmonary fibrosis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA response defined as a reduction in serum PSA levels of at least 50%
- Secondary Outcome Measures
Name Time Method Safety, PSA flare, time to PSA failure